Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease

被引：0
|
作者：
Strik, A. [1 ]
van den Brink, G. [1 ]
Ponsioen, C. [1 ]
Mathot, R. [2 ]
Lowenberg, M. [1 ]
D'Haens, G. [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Gastroenterol & Hepatol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Hosp Pharm, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP066
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [1] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A. S.
    van den Brink, G. R.
    Ponsioen, C.
    Mathot, R.
    Loewenberg, M.
    D'Haens, G. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
  • [2] ANTI-DRUG ANTIBODIES (ADA): ASSAY PERFORMANCE IN PATIENTS TREATED FOR INFLAMMATORY BOWEL AND RHEUMATIC DISEASE WITH BIODRUGS, ADALIMUMAB AND INFLIXIMAB
    O'Donnell, J.
    Liu, J.
    Keating, P.
    Hock, B.
    Spellerberg, M.
    Barclay, M.
    Stamp, L.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 15 - 15
  • [3] Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays
    Barclay, Murray L.
    Karim, Shwan
    Helms, Esther T. Johanna
    Keating, Paula E.
    Hock, Barry
    Stamp, Lisa K.
    Schultz, Michael
    INTERNAL MEDICINE JOURNAL, 2019, 49 (04) : 513 - 518
  • [4] EFFECT OF ADDITION OF AN IMMUNOMODULATOR ON OUTCOMES IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON ANTI-TNF MONOTHERAPY WITH NEW ANTI-DRUG ANTIBODIES
    Portocarrero, Andrea
    Chona, Deepika
    Hellmann, Jennifer
    Minar, Phillip P.
    Rosen, Michael J.
    GASTROENTEROLOGY, 2019, 156 (06) : S617 - S617
  • [5] Importance of Determining Anti-drug Antibodies in the Treatment of inflammatory Bowel Disease with Infliximab
    Langmann, Anna
    Langmann, Peter
    INTERNIST, 2019, 60 : S8 - S8
  • [6] The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
    Neasa Mc Gettigan
    Aman Shah Afridi
    Grace Harkin
    Caroline Lardner
    Stephen Patchett
    Danny Cheriyan
    Gavin Harewood
    Karen Boland
    Aoibhlinn O’Toole
    International Journal of Colorectal Disease, 2021, 36 : 1231 - 1241
  • [7] The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
    Mc Gettigan, Neasa
    Afridi, Aman Shah
    Harkin, Grace
    Lardner, Caroline
    Patchett, Stephen
    Cheriyan, Danny
    Harewood, Gavin
    Boland, Karen
    O'Toole, Aoibhlinn
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (06) : 1231 - 1241
  • [8] Risk factors for the development of anti-drug antibodies to infliximab and adalimumab in Crohn's disease
    Khoo, E.
    Lord, A.
    Hanigan, K.
    Croft, A.
    Radford-Smith, G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S378 - S379
  • [9] Anti-drug Antibodies Inhibit Neutralization of TNF-alpha in Infliximab Treated Patients with Inflammatory Bowel Disease (IBD)
    Eser, A.
    Vogelsang, H.
    Reinisch, S.
    Novacek, G.
    Dejaco, C.
    Kazemi-Shirazi, L.
    Primas, C.
    Lichtenberger, C.
    Brehovsky, S.
    Singh, S.
    Jain, A.
    Reinisch, W.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S304 - S305
  • [10] Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
    Pekala, Anna
    Filip, Rafal
    Aebisher, David
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
12345